New Therapies

Bringing New Therapies to the Bedside

​All new therapies, biomarkers or other medical discoveries must be tested in patients through clinical trials. This complex and demanding process requires a high degree of compassion and medical expertise, as well as communication and organizational skills. Thus many specialized experts working closely as a team.

The IPCR has two integrated clinical trials teams: one focused on developing and testing therapies for advanced disease; and the other developing and testing therapies designed to be used with surgery and radiotherapy for treating localized prostate cancers (those in which tumors are only in the prostate and have not spread to other organs in the body).

Many of the clinical trials are unique to Seattle. Several new research studies, called novel studies, involve the first evaluation of new therapeutic treatments in people. Other trials involve more than one research institution and originate through cooperation with leading national clinical trials groups involving the major cancer centers in the United States and abroad.

IPCR clinical trials include some of the most innovative therapies currently being evaluated nationally. The institute includes one of 10 National Cancer Institute-funded prostate cancer Specialized Programs of Research Excell​ence (SPORE). As a result, IPCR physicians participate in new therapy trials often available only to that group, allowing UW Medicine patients to receive new, better treatments as quickly as possible.

IPCR clinical trials researchers are also members of the Department of Defense Prostate Cancer Clinical Trials Consortium and have access to many trials conducted by this special group of 12 leading prostate cancer centers in the United States.

Our clinical trial accomplishments

Molecular Studies in localized disease:

  • Neoadjuvant therapy, giving other treatments before the traditional primary treatment for a localized disease, has improved the outcomes of many cancer patients. In the past, these therapies have been slow to reach many cancer patients because their success could be judged only after many years of follow-up and study.

    IPCR researchers have helped pioneer a new, quicker approach for evaluating neoadjuvant therapies. At the time of the primary surgery or just before radiation therapy, physicians take a cancer specimen for molecular analysis. In this way, scientists are able to tell more quickly whether a new therapy is effective by looking at the way molecules in the cancer specimen react to the therapy.

  • So far, the IPCR team has conducted large neoadjuvant molecular studies of chemotherapy drugs and, more recently, of newer hormone therapies. Many more molecular neoadjuvant studies are in the planning stages.
  • Every tumor (and patient) has unique characteristics, dictated by gene variations. The molecular analyses of cancers provide an opportunity for researchers to develop a personalized approach to treating and following a patient’s particular cancer.

Innovative treatments for advanced disease:

  • Although suppressing testosterone and administering chemotherapy prolong survival for men with advanced prostate cancer, most cancers eventually develop resistance to these interventions. IPCR investigators have conducted Phase I, first-in-human, trials designed to block tumors’ resistance mechanisms, allowing patients in the Northwest to be the first recipients of treatments resulting from these promising laboratory findings.
  • Encouraging results from novel studies involving antibodies targeting the Insulin-like Growth Factor-1 Receptor (IGF-1R) and small molecules targeting the stress response protein clusterin, have led to clinical trials designed to substantially improve the longevity of men with advanced prostate cancer.
  • IPCR investigators are also key participants in trials involving new effective therapies developed elsewhere, such as Provenge, abiraterone, and MDV-3100.

49 thoughts on “New Therapies”

  7. TopFollow App

    If you want guaranteed popularity on Instagram, topfollow is the go-to mobile app.
    It gives you real-time followers and likes on your posts and profile. The …

  14. ern

    Extremely decent blog and articles. I am really extremely glad to visit your blog. Presently I am discovered what I really need. I check your blog regularly and attempt to take in something from your blog. Much obliged to you and sitting tight for your new post.슬롯사이트

  16. Colors Tv

    Pyar Ke Saat Vachan Dharam Patni’ is a fiction TV show starring Fahmaan Khan and
    Kritika Singh Yadav in the lead roles of business tycoon. Its Colors Tv Serial hd.

  24. DavidGr

    Very helpful content and it benefitted me a lot. As we are discussing medical here, I would love to share a very helpful site with good content Memon Medical Institute. Here you can read a lots of authentic and good stuff.

  39. 劇迷

    隨時隨地輕鬆追上最新影劇資訊 ! 涵蓋電影、電視劇、動漫、綜藝、陸劇、韓劇、美劇、台劇、日劇、BL、泰劇、紀錄片等 劇迷

  43. ern

    Your article is what I’ve been looking for for a long time. I’m happy to find you like this. Could you visit my website if you have time? I’m sure you’ll find a post of interest that you’ll find interesting. ,슬롯사이트

Leave a Reply

Your email address will not be published.